Prediction of Acute Toxicity Grade ≥ 3 in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Intensity Modulated Radiotherapy and Concurrent Low-Dose Cisplatin-Reference-Cited by-同舟云学术

Prediction of Acute Toxicity Grade ≥ 3 in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Intensity Modulated Radiotherapy and Concurrent Low-Dose Cisplatin

Published:2013-09 Issue:5 Volume:14 Page:541-548
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Uyterlinde Wilma,Belderbos José,Baas Claudia,van Werkhoven Erik,Knegjens Joost,Baas Paul,Smit Arthur,Rikers Chris,van den Heuvel Michel

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer;Schaake-Koning;N Engl J Med,1992

2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010

3. Concurrent chemoradiotherapy in non-small cell lung cancer;O'Rourke;Cochrane Database Syst Rev,2010

4. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973);Belderbos;Eur J Cancer,2007

5. Acute esophagus toxicity in lung cancer patients after intensity modulated radiotherapy and concurrent chemotherapy;Kwint;Int J Radiat Oncol Biol Phys,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dynamics and prognostic value of FDG PET-metrics in weekly monitoring of (chemo)radiotherapy for NSCLC;Radiotherapy and Oncology;2021-07

2. In response to Park, et al.;Radiotherapy and Oncology;2020-06

3. Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients;Radiotherapy and Oncology;2020-02

4. Dose–volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy;Radiotherapy and Oncology;2020-02

5. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib;BMC Cancer;2019-09-10